After transplant, three received rituximab, and three patients received prophylactic EBVspecific cytotoxic T-lymphocytes. Only one patient developed recurrent LPD posttransplant, which responded to rituximab. All transplanted patients survive free of LPD and cured of their PID, at median follow-up of four years (range one to seven years).
INTRODUCTION
Lymphoproliferative disease (LPD) can arise in a range of situations where there is impaired immunity, and is a recognized complication of primary immunodeficiency (PID) and immunodysregulatory syndromes. In PID-associated LPD (PID-LPD), the disease is most commonly extra-nodal, B-cell in origin and driven by EBV 1 . Typical predisposing PIDs include Wiskott-Aldrich syndrome, ataxia telangiectasia, X-linked lymphoproliferative syndrome, common variable immunodeficiency, and hyper-IgM syndrome [2] [3] [4] .
Historically, the outcome of PID-LPD was very poor, with reported mortality rates nearing 70% where the disease was unresponsive to conventional chemotherapy 5 For personal use only. on . by guest www.bloodjournal.org From (although heavily immunosuppressive) reduced-intensity conditioning (RIC) SCT regimes, to cure the underlying PID 6 , although recent reports have suggested that RIC SCT in this group may be associated with an increased risk of PTLD 7 . Similar RIC regimes have been used to treat adults with LPD arising de novo 8 suggesting that myeloablative regimes may not be necessary to control these diseases. Following SCT, the combination of molecular screening for EBV viraemia and prophylactic/pre-emptive therapy with rituximab 9 and EBV-specific CTLs significantly reduces the risk of the development PTLD 10 .
Here we describe our experience using this approach to achieve long-term cure of LPD in patients with PID.
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MATERIALS & METHODS
During the period 1999-2006, eight children presented with LPD complicating PID or immunodysregulatory syndromes at this hospital. Their details are displayed in Table 1 .
Five patients had primary immunodeficiencies, the other three had evidence of an immunodysregulatory disorder. Although the LPD was clinically heterogeneous, histologically most patients had either monomorphic LPD with a phenotype of diffuse large B-cell lymphoma, or Hodgkin disease. Biopsies from 5 cases showed evidence of EBV by in situ hybridization for EBV-encoded RNA (EBER). Biopsies in two cases showed no evidence that the LPD was EBV-driven.
LPD in five out of six patients responded to chemotherapy, the other (Patient 3) requiring rituximab to control disease. Two patients relapsed following chemotherapy; one relapsing twice (Patient 5). Patients 1 and 5 were maintained on weekly rituximab into transplant. In total, six patients received rituximab prior to transplant to treat their LPD.
All eight patients received non-myeloablative RIC SCT. Due to significant pre-existing organ dysfunction, Patient 1 was conditioned with low dose total body irradiation (TBI). 11 . Two patients with previous cryptosporidial disease also received azithromycin and paromomycin.
As BMT was undertaken to cure both the underlying immunological condition as well as the secondary LPD, cure was defined to include resolution of both problems as judged by clinical and immunological parameters. Patients were monitored following transplantation with regular assessment of immune function and chimerism, as described previously 12 .
Patients 1-4, treated prior to October 2003, were screened for EBV viraemia weekly by DNA polymerase chain reaction (PCR) amplification of the EBV internal repeat region on whole blood 13 . If EBV DNA was detected in whole blood, a semi-quantitative assay to determine viral load was performed using serial dilutions of patient plasma. For patients 5-8 screening was performed with real-time quantitative PCR using the whole blood 14 .
Patients were closely monitored for symptoms attributable to EBV and PTLD. Those with EBV viraemia were categorized as either (1) asymptomatic, (2) symptomatic viraemia ( fever for which no other cause could be identified) or (3) PTLD.
Rituximab was used at doses of 375mg/m 2 on a weekly basis in patients with rising EBV viraemia, even in the absence of symptoms. Polyclonal EBV-specific cytotoxic T 
RESULTS
The incidence, manifestations and treatment of post-SCT EBV viraemia in the eight transplanted patients are shown in Table 2 The highest viral load amongst patients not receiving rituximab or EBV-CTLs was 50,000 copies/ml.
Three patients also developed CMV viraemia, one with retinitis requiring a ganciclovir implant. A further patient had retinitis due to VZV.
Of the two patients who had a reduction in immunosuppresion to treat EBV, one (Patient 4) developed skin GVHD as a result, responding to topical steroids. Details of other complications are shown in Table 2 . These patients have been followed up for a median of four years (range one to seven years) (see Table 3 ). All patients survived, and are currently clinically well. Seven patients had full donor chimerism at initial engraftment in both lineages. In Patient 3, this dropped to high-level mixed chimerism by one year post-transplant, but has remained stable at that level since. Patient 1 achieved high-level mixed chimerism at initial engraftment and this has remained stable since. Initial studies suggested that polymorphic PTLD could be monoclonal or polyclonal whereas the majority of monomorphic PTLD are monoclonal. However, molecular analysis reveals that virtually all cases of both polymorphic and monomorphic PTLD are monoclonal. Thus, the assessment of clonality by molecular techniques does not add significant clinically important prognostic information 22 .
The majority of the LPDs in the setting of primary immunodeficiency / immunodysregulation are aggressive, and the prognosis appears to be related to both the specific underlying immune disorder in addition to the specific subtype of lymphoproliferation. Such cases are generally histopathologically reported according to their phenotype and although precursor lesions have been reported in primary immunodeficiencies, the distinct categories of early lesions, polymorphic and monomorphic PTLD used in the post-transplant setting may not be directly applicable in this setting although are commonly used 22 .
The largest previous report of the outcome of LPD in the PID setting 23 described 12 cases, with similar predominance of large B-cell lymphoma. Nine of these 12 patients died, four from the LPD, three from chemotherapy toxicity, and two following allogeneic myeloablative SCT. These patients were treated in a range of centres over a long period of time, prior to the availability of rituximab, RIC SCT, pre-emptive EBV PCR screening, and the use of EBV-CTLs.
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The prolonged period of profound immunosuppression associated with RIC SCT 24;25 requires vigilance and screening for rising EBV loads post-transplant. Delayed development of EBV-CTL after SCT is associated with increased risk of EBV reactivation and PTLD following conventional intensity conditioned SCT 26 , and has been shown to occur even later in RIC SCT 27 . In the RIC setting, in vivo use of alemtuzumab contributes to the prolonged immunodeficiency post-SCT and is associated with a significant risk of EBV reactivation 7 . PTLD can be avoided by using rituximab preemptively in such high risk patients 28 . Three patients described here received preemptive rituximab, and none developed PTLD.
The use of EBV specific CTLs has been shown to be safe and efficacious in the SCT setting, both prophylactically and for the treatment of established PTLD 29;30 . There are disadvantages with this approach. It takes 8-10 weeks to generate CTLs. Furthermore, in the context of established PTLD localised inflammatory reactions and necrosis may occur 31 . The safest use of EBV-CTLs in PID patients with pre-existing EBV-LPD undergoing SCT is therefore prophylactic, as was the case for three of the patients here.
One case of rising EBV load after RIC transplantation for XLP was successfully treated using a booster infusion of donor CD34+ cells 32 . Whilst donor CD34+ cells may be available more readily than ex vivo manufactured EBV-CTLs, the time required for CD34+ cell engraftment and subsequent in vivo EBV-CTL reconstitution may counter this benefit. The three patients who received prophylactic EBV-CTLs in this series all remained asymptomatic. Although it is not possible to relate the peak EBV viral loads to
clinical disease manifestions in this series, this pre-emptive approach appears safe and efficacious even in this particularly high risk population.
The initial engraftment results reported here reflect the previous experience of this group with RIC SCT. It has previously been reported that a loss of full chimerism occurs in some recipients of unrelated donor (UD) grafts following RIC SCT over the course of the first year 33 . Only one of seven patients (14%) reported here had a loss in full donor chimerism, lower than that seen in the UD RIC series. However, given the small number of patients reported here, this difference may be of no significance.
Avoidance of RIC SCT has been suggested in the transplantation of conditions such as XLP 34 in view of the significant risks of PTLD following RIC 7 . However, this risk must be offset against the conditioning-related organ toxicity and late effects of conventionalintensity conditioning. With the approach to EBV-surveillance and pre-emptive therapy described above, our results show that it is possible to undertake RIC SCT in patients with primary immunodeficiency or immunodysregulatory disorders, even in the presence of pre-existing LPD. For 
